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Abstract
Background: Atrial fibrillation (AF) is associated with increased mortality in heart failure (HF) patients.
Objective: To evaluate whether the risk of AF patients can be precisely stratified by relation with cardiopulmonary 
exercise test (CPET) cut-offs for heart transplantation (HT) selection.
Methods: Prospective evaluation of 274 consecutive HF patients with left ventricular ejection fraction ≤ 40%. The 
primary endpoint was a composite of cardiac death or urgent HT in 1-year follow-up. The primary endpoint was analysed 
by several CPET parameters for the highest area under the curve and for positive (PPV) and negative predictive value 
(NPV) in AF and sinus rhythm (SR) patients to detect if the current cut-offs for HT selection can precisely stratify the AF 
group. Statistical differences with a p-value <0.05 were considered significant.
Results: There were 51 patients in the AF group and 223 in the SR group. The primary outcome was higher in the AF 
group (17.6% vs 8.1%, p = 0.038). The cut-off value of pVO2 for HT selection showed a PPV of 100% and an NPV of 
95.5% for the primary outcome in the AF group, with a PPV of 38.5% and an NPV of 94.3% in the SR group. The cut-off 
value of VE/VCO2 slope showed lower values of PPV (33.3%) and similar NPV (92.3%) to pVO2 results in the AF group.
Conclusion: Despite the fact that AF carries a worse prognosis for HF patients, the current cut-off of pVO2 for HT 
selection can precisely stratify this high-risk group. (Arq Bras Cardiol. 2020; 114(2):209-218)
Keywords: Atrial Fibrillation/mortality; Peak Expiratory Flow Rate; Exercise Test; Oxygen Consumption; Heart 
Failure; Prognosis.
Introduction
Heart failure (HF) and atrial fibrillation (AF) often coexist,1 
with AF occurring in some reports in more than 50% of HF 
patients, and HF in more than one-third of AF patients.2 Since 
the burden of each is growing, they have been called the two 
new epidemics of cardiovascular (CV) disease.3 
The presence of AF in HF patients is associated with adverse 
hemodynamic consequences, which may exacerbate HF, 
increasing morbidity and mortality.4-6
The cardiopulmonary exercise test (CPET) is a powerful 
predictor of mortality in HF patients and is used as the criterion 
standard for the need for heart transplantation (HT),7 with peak 
O2 consumption (pVO2) and the relation between ventilation 
and CO2 production (VE/VCO2 slope) as the most used risk 
assessment tools.8 However, less information is known about 
whether HF patients with AF can be precisely stratified with the 
current CPET cut-offs for HT selection. Since the combination 
of HF and AF provide a worse prognosis, a timely referral for 
HT or mechanical circulatory support could be extraordinarily 
important to reduce the negative prognostic effect of AF in 
HF patients.
The present study seeks to compare the prognostic 
importance in HF patients of CPET parameters in AF versus 
sinus rhythm (SR) patients. 
Methods
The investigation conforms to the principles outlined in the 
Declaration of Helsinki. The institutional ethics committee 
approved the study protocol. All patients provided written 
informed consent.
Patient population and study protocol
The study included a single centre analysis of 274 
consecutive HF patients referred to our institution with left 
ventricular ejection fraction (LVEF) ≤ 40% and New York 
Heart Association (NYHA) class II or III, from 2009 to 2016. 
All the patients were referred for evaluation with HF team 
and possible indication for HT or mechanical circulatory 
support. Patients with elective HT during the follow-up 
period (patients who had indication for HT and a heart 
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Prospective follow-up included initial evaluation within a 
period of one month in each patient with:
• Clinical data including etiology of HF, implanted devices, 
medication, comorbidities, NYHA class and Heart Failure 
Survival Score (HFSS);9 
• Laboratory data;
• Electrocardiographic data; 
• Echocardiographic data;
• CPET data. 
Patients were excluded if one of the following: 
• Age < 18 years;
• Planned percutaneous coronary revascularization or 
cardiac surgery; 
• Elective HT in the follow-up period;
• Exercise-limiting comorbidities (cerebrovascular 




All patients were followed-up for 12 months from the date 
of completion of the aforementioned complementary exams.
The primary endpoint was a composite of cardiac death 
or urgent HT (occurring during an unplanned hospitalization 
with dependency of inotropes for worsening HF). Data were 
obtained from the outpatient clinic visits and medical charts 
review and was complemented with a standardized telephone 
interview to all patients at 12 months of follow-up. Secondary 
endpoints included all-cause mortality, sudden cardiac death 
and death for worsening HF. 
Definition of atrial fibrillation
Only persistent or permanent AF was considered for the 
analysis. The diagnosis was made by electrocardiographic 
recording in the initial evaluation. 
Cardiopulmonary exercise testing
A maximal symptom-limited treadmill CPET was performed 
using the modified Bruce protocol (GE Marquette Series 2000 
treadmill). Tha gas analysis was preceded by the calibration 
of the equipment. Minute ventilation, oxygen uptake and 
carbon dioxide production were acquired breath-by-breath, 
using a SensorMedics Vmax 229 gas analyser. The pVO2 was 
defined as the highest 30-second average achieved during 
exercise and was normalized for body mass.10 The anaerobic 
threshold was determined by combining the standard methods 
(V-slope preferentially and ventilatory equivalents). The VE/
VCO2 slope was calculated by least-squares linear regression, 
using data acquired throughout the whole exercise. Several 
composite parameters of CPET were also calculated. Patients 
were encouraged to perform exercise until the respiratory 
exchange ratio (RER) was ≥1.10.
Statistical analysis
All analyses compare AF patients with SR patients. Data 
were analysed using the software Statistical Package for 
the Social Science for Windows, version 24.0 (SPSS Inc, 
Chicago IL). 
Baseline characteristics were summarized as frequencies 
(percentages) for categorical variables, as means and 
standard deviations for continuous variables when normality 
was verified and as median and interquartile range when 
normality was not verified by the Kolmogorov-Smirnov test. 
The Student’s t-test for independent samples or the Mann-
Whitney test when normality was not verified were used for 
the analysis of the variables. 
Univariable and multivariable Cox proportional-hazards 
models were applied, with p values for time-to-event 
analyses being based on log-rank tests, and hazard ratios for 
treatment effects and 95% confidence intervals presented 
to study the combined endpoint considering the follow-up 
time of 12 months. 
For selecting patients who would benefit from early 
selection for HT or mechanical circulatory support, the primary 
endpoint was analysed by several CPET parameters for the 
highest area under the curve (AUC) in the 12 months’ follow-
up. Hanley & McNeil test was used to compare two correlated 
receiver operating characteristics curves.11 
The guideline recommended cut-off value of pVO2 
(pVO2 ≤ 12 ml/kg/min or ≤ 14 ml/kg/min without beta-
blockers (BB)) and VE/VCO2 slope (VE/VCO2 slope > 35 with 
a RER < 1.05) for HT7 selection were analysed (and compared 
for positive and negative predictive value (PPV and NPV, 
respectively) in our population of AF and SR patients. 
Statistical differences with a p-value < 0.05 were 
considered significant.
Results
Overview of AF and SR groups
A total of 274 patients were enrolled in the study, with 
51 patients in the AF group and 223 in the SR group. The 
baseline characteristics of SR and AF groups are presented 
and compared in Table 1. 
In regard to clinical data, AF patients were older 
(57.96 ± 8.61 vs 52.61 ± 12.53, p < 0.001) and had a 
lower percentage of females. Medication with angiotensin-
converting enzyme inhibitors, angiotensin receptor blockers, 
BB and mineralocorticoid receptor antagonists were similar 
and highly prevalent in both groups, and no differences were 
found regarding implantable cardioverter-defibrillator and 
cardiac resynchronization therapy between the two groups. 
There were no significant differences for sodium and NT-
proBNP, but glomerular filtration rate (GFR) values were lower 
in the AF group (65.03 ± 29.05 vs 76.84 ± 30.20, p = 0.012). 
Higher percentage of right ventricular dysfunction (40.0% 
vs 13.0%, p < 0.001) and lower values of LVEF (24.96 ± 7.44 
vs 27.91 ± 7.23, p = 0.010), revealed a worse biventricular 
function in AF group. 
CPET data showed no differences regarding heart rate 
parameters, but the AF group had lower baseline and maximal 
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Table 1 – Baseline characteristics of AF and SR groups
SR - n = 223 AF - n = 51 p for ≠ between groups
Clinical data – characteristics
Age 52.61 ± 12.53 57.96 ± 8.61 < 0.001
Female (%) 61 (27.4%) 6 (11.8%) 0.019
BMI1 (kg/m2) 26.80 ± 4.07 27.47 ± 4.78 0.361
Ischemic etiology (%) 90 (40.4%) 14 (27.5%) 0.087
ACEi2/ARA3 (%) 211 (96.3%) 50 (98.0%) 0.544
BB4 (%) 179 (80.3%) 40 (78.4%) 0.768
MRA5 (%) 184 (72.2%) 38 (74.5%) 0.677
Diabetes (%) 43 (21.4%) 10 (22.7%) 0.846
Baseline6 ICD (%) 109 (49.8%) 27 (52.9%) 0.493
Baseline7 CRT (%) 48 (21.5%) 12 (23.5%) 0.781
HFSS8 8.77 ± 0.95 8.22 ± 0.93 < 0.001
Laboratorial data
Glomerular filtration rate (ml/min) 76.84 ± 30.20 65.03 ± 29.05 0.012
Sodium (mEq/L) 137.8 (135.7-139.3) 136.9 (133.6-139.3) 0.052
NT-proBNP (pg/ml) 2,046.79 ± 2,223.07 3,247.38 ± 4,578.571 0.097
Echocardiographic data
LVEDD9 (mm/m2) 38 (35-43) 38 (35-43) 0.237
LVEF10 (%) 29 (22-34) 26 (20-30) 0.010
MR III-IV11 (%) 87 (39.0%) 12 (23.5%) 0.073
RV dysfunction (%) 29 (13.0%) 22 (40%) < 0.001
CPET data
Initial HR13 82 (72-92) 83 (70-100) 0.232
Maximal HR 137 (121-157) 130 (115-179) 0.747
Maximal HR predicted (%) 82.77 ± 12.86 86.88 ± 23.37 0.230
Delta HR during exercise 53 (39-71) 52 (34-64) 0.636
HHR114 17 (12-26) 16 (10-25) 0.624
Initial SBP15 115 (110-125) 1,110 (100-120) 0.026
Maximal SBP 155.30 ± 26.83 145.92 ± 28.98 0.028
Duration of CPET16 (min) 10.83 ± 3.99 8.53 ± 4.30 < 0.001
Peak RER17 1.10 ± 0.09 1.11 ± 0.09 0.340
pVO2 (ml/kg/min) 20.27 ± 5.54 17.81 ± 5.55 0.005
pVO2 predicted (%) 68.12 ± 17.65 63.12 ± 18.29 0.072
VE/VCO2 slope 30.64 ± 6.78 34.33 ± 8.88 0.006
OUES 1.83 ± 0.58 1.64 ± 0.60 0.035
AT18 time (minutes) 7.49 ± 3.44 5.49 ± 3.63 < 0.001
pVO2 (ml/kg/min) at AT 16.35 ± 4.29 14.29 ± 4.32 0.002
Values are mean ± standard deviation or median (interquartile range); p values are calculated by Student´s T-test for independent samples or Mann-Whitney U test as 
appropriate. SR: sinus rhythm; AF: atrial fibrillation; BMI: body mass index; ACEi: angiotensin-converting enzyme inhibitors; ARA: angiotensin receptor blockers; BB: 
beta-blockers; MRA: mineralocorticoid receptor antagonists; ICD: implantable cardioverter-defibrillator; CRT: cardiac resynchronization therapy; HFSS: Heart Failure 
Survival Score; LVEDD: left ventricular end-diastolic diameter; LVEF: left ventricular ejection fraction; MR: mitral regurgitation; RV: right ventricular; HR: heart rate; 
HRR1: heart rate recovery in the first minute after finishing CPET; SBP: systolic blood pressure; CPET: cardiopulmonary exercise test; RER: respiratory exchange 
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Table 2 – Adverse events at 12 months follow-up
Adverse events at 12 months 
follow-up SR - n (%) AF - n (%) p
Combined endpoint 18 (8.1%) 9 (17.6%) 0.038
Total mortality 14 (6.3%) 9 (17.6%) 0.008
Cardiac mortality 12 (5.4%) 6 (11.8%) 0.097
Sudden cardiac death 5 (2.2%) 4 (7.8%) 0.043
Death for worsening HF 7 (3.1%) 2 (3.9%) 0.777
Urgent HT 6 (2.7%) 3 (5.9%) 0.249
Mechanical circulatory support 0 (0%) 0 (0%) 1.000
AF: atrial fibrillation; HF: heart failure: HT: transplantation; SR: sinus 
rhythm.
Table 3 – Univariate Cox proportional-hazards analysis (non-CPET parameters)
Characteristics
All SR AF
Wald Hazard ratio 95% CI p Wald
Hazard 
ratio 95% CI p Wald
Hazard 
ratio 95% CI p
Age 0.092 0.995 0.965-1.026 0.762 0.768 0.984 0.950-1.020 0.381 0.057 1.010 0.933-1.093 0.811
Gender 0.524 0.699 0.265-1.845 0.469 1.041 0.525 0.152-1.812 0.308 1.188 2.397 0.498-11.547 0.276
BMI 1.175 0.947 0.859-1.045 0.278 0.183 0.974 0.863-1.099 0.669 1.906 0.887 0.748-1.052 0.167
Beta-Blocker 5.139 2.469 1.130-5.393 0.023 4.259 2.713 1.051-6.998 0.039 0.877 1.941 0.484-7.779 0.349
Diabetes 0.130 1.197 0.451-3.174 0.718 0.027 0.910 0.297-2.792 0.869 0.691 2.416 0.302-19.326 0.406
Baseline CRT 1.614 1.995 0.687-5.790 0.204 1.047 2.160 0.494-9.446 0.306 1.807 2.940 0.610-14.167 0.179
HFSS 34.893 0.233 0.144-0.378 < 0.001 22.674 0.233 0.128-0.424 < 0.001 8.600 0.243 0.095-0.626 0.003
Glomerular filtration 
rate 3.520 0.586 0.971-1.101 0.061 2.578 0.985 0.967-1.003 0.108 0.205 0.994 0.969-1.020 0.650
Sodium 27.303 0.787 0.720-0.861 < 0.001 14.635 0.766 0.668-0.878 < 0.001 7.668 0.839 0.726-0.947 0.006
NT-proBNP 20.456 8.212 2.234-12.367 < 0.001 15.171 6.263 1.894-10.223 < 0.001 3.187 2.335 1.285-4.534 0.004
LVEDD 5.670 1.072 1.012-1.135 0.017 3.001 1.077 0.990-1.171 0.083 1.443 1.049 0.970-1.135 0.230
LVEF 18.934 0.887 0.840-0.936 < 0.001 13.810 0.884 0.828-0.943 < 0.001 3.351 0.912 0.826-0.998 0.049
RV dysfunction 21.377 3.758 2.144-6.588 < 0.001 6.160 2.846 1.246-6.499 0.013 8.346 4.267 1.594-11.419 0.004
SR: sinus rhythm; AF: atrial fibrillation; CI: confidence interval; BMI: body mass index; CRT: cardiac resynchronization therapy; HFSS: Heart Failure Survival Score; 
LVEDD: left ventricular end-diastolic diameter; LVEF: left ventricular ejection fraction; RV: right ventricular.
the two groups were also observed with prognostic measures 
of CPET, with a worse status in AF group revealed by a lower 
CPET duration, pVO2, oxygen uptake efficiency slope (OUES), 
time to anaerobic threshold (AT), pVO2 at AT and a higher VE/
VCO2 slope (Table 1).
Primary and secondary endpoints
At 1 year, the primary endpoint (cardiac death or urgent 
HT) had occurred in 27 (9.9%) patients as represented 
in Table 2. There were no patients requiring mechanical 
circulatory support. The AF group had more events regarding 
the combined endpoint (17.6% vs 8.1%, p = 0.038), with 
cardiac mortality alone showing a trend for a worse prognosis 
in the AF group (11.8% vs 5.4%, p = 0.097), with no statistical 
difference regarding urgent HT (5.9% vs 2.7%, p = 0.249). 
Secondary endpoints showed higher all-cause mortality 
(17.6% vs 6.3%, p = 0.008) and a higher sudden cardiac death 
(7.8% vs 2.2%, p = 0.043) in the AF group, with no difference 
regarding death for worsening HF (3.9% vs 3.1%, p = 0.777). 
Complete data of univariable Cox analysis for prediction 
of the primary endpoint is presented in Table 3 and Table 4. 
HFSS, Sodium, NT-proBNP, right ventricular dysfunction, 
LVEF, CPET duration, heart rate recovery in the first minute 
after finishing CPET (HHR1) and initial and maximal SBP 
during CPET were predictors of the primary endpoint in 
both groups. 
With the exception of HHR1, heart rate (HR) parameters 
during CPET were only predictors of the primary endpoint in 
the AF group, as seen with lower values of maximal HR, lower 
values of maximal (%) predicted HR and a lower variation of 
the HR during exercise, for patients with AF for whom the 
primary endpoint occurred and for those for whom it did not, 
respectively (Table 4).
On the other hand, the use of BB was only a predictor of 
the primary endpoint in the SR group (Table 3). 
Relationship between CPET prognostic parameters and 
primary outcome
The power to predict the primary outcome by CPET 
parameters is represented in the supplementary index. 
Univariate Cox analysis shows that pVO2, pVO2 (%) predicted, 
pVO2 at AT, VE/VCO2 slope and OUES are all predictors of the 
primary outcome in both groups (p < 0.05 for all). 
In addition to the Cox analysis, these CPET parameters 
were analysed for the highest AUC in the 12 months’ follow-
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Table 4 – Univariate Cox proportional-hazards analysis (CPET parameters)
Characteristics
All SR AF
Wald Hazard ratio 95% CI p Wald
Hazard 
ratio 95% CI p Wald
Hazard 
ratio 95% CI p
Initial HR 0.220 1.006 0.983-1.029 0.639 2.265 1.024 0.993-1.056 0.132 1.414 0.977 0.940-1.015 0.234
Maximal HR 6.259 0.982 0.967-0.996 0.012 0.644 0.992 0.974-1.011 0.422 5.706 0.973 0.951-0.955 0.017
Maximal HR(%)
predicted 8.343 0.962 0.937-0.968 0.004 1.864 0.975 0.941-1.011 0.172 5.590 0.958 0.924-0.993 0.018
Delta HR during 
exercise 10.141 0.969 0.951-0.988 0.001 3.324 0.979 0.956-1.002 0.068 6.527 0.960 0.930-0.991 0.011
HHR1 22.484 0.837 0.778-0.901 < 0.001 15.623 0.829 0.755-0.910 < 0.001 5.939 0.869 0.777-0.973 0.015
Initial SBP 13.913 0.946 0.919-0.974 < 0.001 8.317 0.951 0.919-0.984 0.004 4.346 0.939 0.885-0.996 0.037
Maximal SBP 21.896 0.959 0.943-0.976 < 0.001 12.029 0.964 0.945-0.984 0.001 7.205 0.954 0.922-0.987 0.007
Duration of CPET 
(min) 26.781 0.756 0.681-0.841 < 0.001 20.636 0.730 0.637-0.836 < 0.001 4.009 0.838 0.704-0.996 0.048
SR: sinus rhythm; AF: atrial fibrillation; CI: confidence interval; HR: heart rate; HHR1: heart rate recovery in the first minute after finishing CPET; SBP: systolic blood 
pressure; CPET: cardiopulmonary exercise test.
AUC value (0.906) followed by predicted pVO2 (%) (0.903), 
with OUES with the lower AUC value (0.798). Despite these 
numerical differences, no statistically significant difference 
was found when the Hanley & McNeil test was applied to 
compare the different AUC values of the CPET parameters. 
In the AF group, predicted pVO2 (%) (0.878) and pVO2 
(0.869) had the highest AUC values. Similarly to the SR group, 
OUES had the lowest AUC value (0.833), but no statistically 
significant difference was found when the Hanley & McNeil 
test was applied to compare these parameters.
The Hanley & McNeil test was applied for comparing each 
CPET AUC parameter in the AF versus SR groups as well, with 
no statistically significant difference found.
Multivariate Cox analysis (Table 5) showed that when pVO2 
and the VE/VCO2 slope are analysed together, significant 
differences were found between SR and AF groups. In the SR 
group, pVO2 lost his predictive power (p = 0.280) while the 
VE/VCO2 slope remained predictive of the primary outcome 
(p = 0.001). In the AF group, the VE/VCO2 slope lost its 
predictive power (p = 0.398) and pVO2 showed a trend 
towards the prediction of the primary outcome (p = 0.091). 
Similar results were found in the multivariate Cox analysis 
of predicted pVO2 (%) and the VE/VCO2 slope in the AF group 
(p = 0.094 and p = 0.145, respectively), while in the SR group 
there was a difference, since predicted (%) pVO2 (p = 0.006) 
and VE/VCO2 slope (p = 0.033) kept their predictive power 
(p = 0.006), while pVO2 had not (p = 0.280). 
OUES lost its predictive power in the multivariate Cox 
analysis in both SR and AF groups when compared with pVO2 
(p = 0.948 and p = 0.539, for SR and AF group respectively) 
Table 5 – Multivariate Cox analysis of CPET1 prognostic parameters
Multivariate Cox analysis
SR AF
Hazard ratio 95% CI p Hazard ratio 95% CI p
1) pVO2 vs VE/VCO2 slope 
pVO2 0.910 0.766-1.080 0.280 0.759 0.551-1.045 0.091
VE/VCO2 slope 1.117 1.045-1.194 0.001 1.050 0.937-1.177 0.398
2) pVO2 (%) predicted vs VE/VCO2 slope 
pVO2 (%) 0.933 0.888-0.981 0.006 0.942 0.879-1.010 0.094
VE/VCO2 slope 1.070 1.005-1.139 0.033 1.078 0.974-1.193 0.145
3) OUES5 vs VE/VCO2 slope 
OUES 1.508 0.388-5.864 0.553 0.624 0.056-6.975 0.701
VE/VCO2 slope 1.170 1.090-1.256 < 0.001 1.123 1.002-1.258 0.046
4) pVO2 vs. OUES
pVO2 0.742 0.597-0.922 0.007 0.623 0.482-0.907 0.014
OUES 1.061 0.183-6.153 0.948 2.335 0.156-34.907 0.539
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Table 6 – Univariate Cox analysis for the primary outcome of the two recommended cardiopulmonary exercise test cut-offs for Heart 
Transplantation selection
SR AF
Hazard ratio 95% CI p Hazard ratio 95% CI p
pVO2 ≤ 12 ml/kg/min 8.673 3.048-24.680 < 0.001 44.220 8.686-225.129 < 0.001
VE/VCO2 slope > 35 20.858 5.985-72.696 < 0.001 5.613 1.164-27.059 0.032
SR: sinus rhythm; AF: atrial fibrillation; CI: confidence interval; pVO2: peak O2 consumption.
Table 7 – Proportion of patients correctely classified at 12 months 
of follow up 
AF SR
pVO2 ≤ 12 ml/kg/min or ≤ 14 
ml/kg/min without BB2 7/7 - 100% 5/13 - 38.5%
pVO2 > 12 ml/kg/min or > 14 ml/
kg/min without BB 42/44 - 95.5% 198/210 - 94.3%
pVO2 ≤ 12 ml/kg/min only in 
patients doing BB 5/5 - 100% 6/8 - 75%
pVO2 > 12 ml/kg/min only in 
patients doing BB 34/35 - 97.1% 161/169 - 95.3%
VE/VCO2 slope > 35 7/21 - 33.3% 14/47 - 29.8%
VE/VCO2 slope ≤ 35 28/30 - 92.3% 173/176 - 98.3%
SR: sinus rhythm; AF: atrial fibrillation; pVO2: peak O2 consumption; BB: 
beta-blockers.
and when compared with the VE/VCO2 slope (p = 0.503 and 
p = 0.701, for SR and AF group respectively).
Cut-off value for HT selection: PPV and NPV for the primary 
outcome
The univariate Cox analysis for the primary outcome 
of the two recommended CPET cut-offs for HT selection7 
(pVO2 ≤ 12 ml/kg/min or ≤ 14 ml/kg/min without BB and 
VE/VCO2 slope ≤ 35) is represented in Table 6, showing 
that in the two groups, both cut-offs remained predictors 
of the outcome. 
In pVO2 ≤ 12 ml/kg/min or ≤ 14 ml/kg/min without BB, 
the PPV for the primary outcome was 100% in the AF group 
and 38.5% in the SR group (Table 7), with a NPV of 95.5% and 
94.3% in the AF and SR groups, respectively. Higher values 
were found when the analysis excluded patients not doing 
BB, with a PPV of 100% and 75%, and a NPV of 97.1% and 
95.3% for the AF and RS groups respectively.
In VE/VCO2 slope > 35 (Table 7), lower values of PPV 
were reported (33.3% and 29.8% for AF and SR groups, 
respectively), with similar NPV to pVO2 (92.3% and 98.3% 
for AF and SR groups, respectively). 
Discussion
The presence of AF is associated with a negative 
prognostic effect in HF, with 50-90% increased mortality 
and HF progression in the Framingham Heart Study.12 Our 
population revealed some baseline differences between SR 
and AF groups, with some of that in previously described 
prognostic markers of HF, as AF patients were older,13,14 
with lower GFR,15-17 with worse right ventricular function18 
and a lower LVEF.19,20 In regard to CPET parameters, our 
AF patients revealed a lower exercise capacity than SR 
patients since they had a higher VE/VCO2 slope and a 
lower CPET duration, pVO2, OUES, time to AT and pVO2 
at AT. As expected, these differences converted in a worse 
prognosis in the AF group, with a 2-fold increase in the 
primary endpoint events (17.6% VS 8.1%, p = 0.038) 
and 3-fold increase in all-cause mortality (17.6% VS 6.3%, 
p = 0.008) in the 1-year follow-up. 
The majority of the predictors of the primary endpoint were 
predictors for both SR and AF groups. The HFSS,21 Sodium,22 
NT-proBNP,23-25 right ventricular dysfunction,18 lower LVEF,19,20 
CPET duration, HHR1,26 and initial and maximal SBP during 
CPET27 were included in this group, with all of them being 
formerly described as prognostic markers in HF patients. 
Differences were found regarding maximal HR and 
variation of HR during the exercise, with lower values in AF 
patients predicting the primary outcome only in that group. 
Patients not using BB were solely predictive of the primary 
outcome in the SR group, but not in the AF group. Whether 
this is in agreement with other studies that failed to reveal 
prognostic benefit from BB in the AF group of HF patients28-30 
or to a underpowered analysis since only 11 patients in the AF 
group were not doing BB cannot be guaranteed.
Cut-off value for HT selection: PPV and NPV for the primary 
outcome
Whether HF patients with AF can be precisely stratified 
with the current CPET cut-offs for HT selection have not been 
specifically studied before. The cut-off value for pVO2 showed 
a PPV for the primary outcome of 100% in the AF group and 
38.5% in the SR group, with a NPV of 95.5% and 94.3% in 
the AF and SR groups, respectively. Hence, despite AF carries 
a worse prognosis in HF patients, the current cut-off of pVO2 
for HT selection can precisely stratified these high-risk patients, 
with no patients under the cut-off misdiagnosed as high risk 
patients and less than 5% of patients above the cut-off having 
the primary outcome in the 1-year follow-up (Figure 1). These 
results suggest that patients under the cut-off of pVO2 should 
be managed accordingly, considering quickly referring for HT 
or mechanical circulatory support, since medical treatment 
is associated with negative outcomes in a 1-year period, and 
that we can be relatively safe in regard to 1-year outcomes of 
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In regard to SR patients, the lower risks associated are 
responsible for a lower value of PPV above the pVO2 cutoff. 
The PPV was raised from 38,5% to 75% when the analysis 
excluded patients not doing BB. The NPV remains high in 
this group (94,3%). 
During exercise, both CO2 output and ventilation increase 
steadily, but in patients with HF, the slope of the relationship 
is increased.31 Previous studies have confirmed the prognostic 
impact of VE/VCO2 in patients with HF, with higher values 
being associated with worse outcomes.32-35 However, the value 
of VE/VCO2 in AF patients with HF is not so well established, 
with differences in results in some trials.36,37 
In our study, with a VE/VCO2 slope > 35, lower values 
of PPV were reported (33.3% and 29.8% for AF and SR 
groups, respectively), with similar NPV compared to pVO2 
results (92.3% and 98.3% for AF and SR groups, respectively, 
figure 1). The power to predict the primary outcome by the 
VE/VCO2 slope, revealed an AUC of 0.906 for the SR group 
(the highest of all the CPET parameters analysed) and 0.844 
in the AF group, with no statistically significant difference 
found when comparing the different AUC values of the CPET 
parameters. These differences in PPV may suggest that despite 
the fact that VE/VCO2 slope could be at least as good for 
prognostic assessment in HF patients as pVO2, the cut-off to 
use with the VE/VCO2 slope is not so well established as the 
cut-off for pVO2 in AF patients. 
One previous study has shown that in a multivariate Cox 
analysis, pVO2 was identified as a sole significant predictor 
of cardiac events in HF patients in SR and the VE/VCO2 
slope in AF patients.38 Our results, however, do not concur 
with the previous results. In fact, our multivariate Cox 
analysis (Table 5) showed that when pVO2 and the VE/VCO2 
slope are analysed together, pVO2 lost its predictive power 
(p = 0.280) while the VE/VCO2 slope remained predictive 
of the primary outcome (p = 0.001) in the SR group. In 
the AF group, the VE/VCO2 slope lost its predictive power 
(p = 0.398) while pVO2 showed a trend for the prediction 
of the primary outcome (p = 0.091). 
Figure 1 – Positive (PPV) and negative predictive value (NPV) of pVO2 and VE/VCO2 slope.
The predicted pVO2 (%) has been demonstrated as a useful 
prognostic marker in previous HF studies.39 In the multivariate 
Cox analysis of predicted pVO2 (%) and the VE/VCO2 slope, 
predicted pVO2 (%) kept his predictive power in the SR group 
(p = 0.006) in contrast to pVO2, while in the AF group, it 
showed a trend towards prediction of the primary outcome (p 
= 0.094) and had the highest AUC predictive value (0.878). 
OUES is derived by plotting VO2 as a function of log10VE, 
which is an approximately linear relation, indicating how 
effectively O2 is extracted and taken into the body.
40 In HF 
patients, OUES is reduced in proportion to disease severity 
and linked to outcome.41,42 In our population, OUES had the 
numerically lower AUC for predicting the primary outcome 
in both AF and SR groups and lost its predictive power in 
the multivariate Cox analysis when compared with pVO2 
and when compared with the VE/VCO2 slope, which is in 
accordance with other previous study.43
Study limitations
There are limitations to our study that should be referenced. 
Even though data was obtained from the outpatient clinic 
visits, medical charts were reviewed and complemented with a 
standardized telephone interview to all patients at 12 months 
of follow-up to collect data for the primary and secondary 
outcomes. Information pertaining to the selection or not of 
rhythm control for the treatment of AF was not gathered. 
Despite this, the goal of the trial was to define, during the initial 
evaluation, which patients needed early indication for HT or 
mechanical circulatory support, reducing the importance of 
the aforementioned information. 
Despite being a seven-year follow-up of patients evaluated 
for HT in one advanced HF centre, the analysed cohort was 
not larger than other studies of the relation between HF and 
AF.2,36,38 However, the sample size is similar to other studies 
that highlighted the value of CPET parameters, including for 
the selection of patients for HT.8,32,35,44,45 
Since patients were referred for a tertiary hospital for the 




Prediction of CPET in HF patients with AF
Arq Bras Cardiol. 2020; 114(2):209-218
1. Kannel WB, Abbott RD, Savage DD, McNamara PM. Epidemiologic 
features of chronic atrial fibrillation: the Framingham study. N Engl J Med. 
1982;306(17):1018-22.
2. Santhanakrishnan R, Wang N, Larson MG, Magnani JW, McManus DD, 
Lubitz SA, et al. Atrial fibrillation begets heart failure and vice versa: temporal 
associations and differences in preserved versus reduced ejection fraction. 
Circulation. 2016;133(5):484-92.
3. Braunwald E. Cardiovascular medicine at the turn of the millennium: 
triumphs, concerns, and opportunities. N Engl J Med. 1997;337(19):1360-9.
4. Pocock SJ, Wang D, Pfeffer MA, Yusuf S, McMurray JJ, Swedberg KB, et al. 
Predictors of mortality and morbidity in patients with chronic heart failure. 
Eur Heart J. 2006;27(1):65-75.
5. Dries DL, Exner DV, Gersh BJ, Domanski MJ, Waclawiw MA, Stevenson 
LW. Atrial fibrillation is associated with an increased risk for mortality and 
heart failure progression in patients with asymptomatic and symptomatic 
left ventricular systolic dysfunction: a retrospective analysis of the 
SOLVD trials. Studies of Left Ventricular Dysfunction. J Am Coll Cardiol. 
1998;32(3):695-703.
6. Carson PE, Johnson GR, Dunkman WB, Fletcher RD, Farrell L, Cohn JN. 
The influence of atrial fibrillation on prognosis in mild to moderate heart 
failure. The V-HeFT Studies. The V-HeFT VA Cooperative Studies Group. 
Circulation. 1993;87(6 Suppl):VI102-10.
7. Mehra MR, Canter CE, Hannan MM, Semigran MJ, Uber PA, Baran DA, et 
al. The 2016 International Society for Heart Lung Transplantation listing 
criteria for heart transplantation: a 10-year update. J Heart Lung Transplant. 
2016;35(1):1-23.
8. Butler J, Khadim G, Paul KM, Davis SF, Kronenberg MW, Chomsky DB, et 
al. Selection of patients for heart transplantation in the current era of heart 
failure therapy. J Am Coll Cardiol. 2004;43(5):787-93.
9. Aaronson KD, Schwartz JS, Chen TM, Wong KL, Goin JE, Mancini DM. 
Development and prospective validation of a clinical index to predict 
survival in ambulatory patients referred for cardiac transplant evaluation. 
Circulation. 1997;95(12):2660-7.
10. Guazzi M, Arena R, Halle M, Piepoli MF, Myers J, Lavie CJ. 2016 Focused 
update: clinical recommendations for cardiopulmonary exercise 
testing data assessment in specific patient populations. Circulation. 
2016;133(24):e694-711.
11. Hanley JA, McNeil BJ. The meaning and use of the area under a receiver 
operating characteristic (ROC) curve. Radiology. 1982;143(1):29-36.
12. Wang TJ, Larson MG, Levy D, Vasan RS, Leip EP, Wolf PA, et al. Temporal 
relations of atrial fibrillation and congestive heart failure and their joint 
influence on mortality: the Framingham Heart Study. Circulation. 
2003;107(23):2920-5.
13. van Veldhuisen DJ, Boomsma F, de Kam PJ, Man in’t Veld AJ, Crijns 
HJ, Hampton JR, et al. Influence of age on neurohormonal activation 
and prognosis in patients with chronic heart failure. Eur Heart J. 
1998;19(5):753-60.
14. Ho KK, Anderson KM, Kannel WB, Grossman W, Levy D. Survival after 
the onset of congestive heart failure in Framingham Heart Study subjects. 
Circulation. 1993;88(1):107-15.
15. Dries DL, Exner DV, Domanski MJ, Greenberg B, Stevenson LW. The 
prognostic implications of renal insufficiency in asymptomatic and 
symptomatic patients with left ventricular systolic dysfunction. J Am Coll 
Cardiol. 2000;35(3):681-9.
16. Al-Ahmad A, Rand WM, Manjunath G, Konstam MA, Salem DN, 
Levey AS, et al. Reduced kidney function and anemia as risk factors for 
mortality in patients with left ventricular dysfunction. J Am Coll Cardiol. 
2001;38(4):955-62.
References
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Despite AF carries a worse prognosis for the HF patients, 
the current cut-off of pVO2 for HT selection can precisely 
stratify this group of high-risk patients. The findings from the 
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under the current cut-off of pVO2 for HT selection should be 
quickly referred for HT or mechanical circulatory support, 
since medical treatment is associated with negative outcomes 
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